N-methyl-D-aspartate (NMDA) receptor antagonists have been shown to protect against focal cerebral ischaemia when administered either before or soon after the onset of ischaemia. However, the precise therapeutic window for protection using these drugs remains to be defined. We studied dextrorphan administration delayed for 2 or 4 h after transient middle cerebral focal ischaemia in a rabbit model.With a 2h delay, the mid (12.5 mg kg
) and high doses (17.5 mg kg −1 h −1 ) provided significant cortical neuroprotection (50% and 58% reduction, respectively), and the low dose (7.5 mg kg
) protected against ischaemic damage in the basal ganglia (52% reduction). Animals having steady-state serum dextrorphan concentrations greater than 2000 ng ml
showed 50% cortical neuroprotection for the 2-h-delay group. No significant neuroprotection was seen in the 4-h-delay group, and the 4 h delay animals with dextrorphan levels greater than 2000 ng ml −1 had more severe ischaemic oedema than the saline controls.These results suggest a narrow temporal therapeutic window for neuroprotection, where delivery of drug delayed by 2 h was efficacious but treatment at 4 h after ischaemia onset was not beneficial and possibly harmful. These findings may have important implications for the treatment of clinical stroke.
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Introduction
The brain is extremely sensitive to significant reductions in blood flow. Partial or complete blockage of blood flow to the brain (ischaemia) seriously compromises neuronal homeostasis. A number of interrelated hypotheses have been postulated as important cellular processes leading to this pathophysiology including cytosolic Ca +2 overload, lactoacidosis, excitatory amino acid neurotoxicity, free radical toxicity during the reperfusion phase, and accumulation of leucocytes with reperfusion (Hallenbeck et al. 1986 , Rothman & Olney 1986 , Choi 1988 , Siesjo 1992a . In particular, excitatory amino acid neurotransmitters, including glutamate, have been implicated in the pannecrosis that occurs during and after an ischaemic result (Rothman & Olney 1987 , Choi 1988 . Evidence suggests that glutamate neurotoxicity occurs in part through NMDA receptors (Goldberg et al. 1987b , Rothman & Olney 1987 . The NMDA neurotoxicity hypothesis is strengthened by the observation that selective antagonism to this receptor is protective against various paradigms of in vitro and in vivo hypoxia-ischaemia injury (Simon et al. 1984 , Goldberg et al. 1987a ,b, Rothman & Olney 1987 , Ozyurt et al. 1988 , Steinberg 1988 , Swan & Meldrum 1990 .
Dextrorphan (DX) is a noncompetitive NMDA receptor antagonist, and has been shown to be neuroprotective during hypoxia or hypoxia/hypoglycaemia in neuronal cultures (Goldberg et al. 1987a ,b, Goldberg & Choi 1993 , Hartley et al. 1993 and in several animal models of focal and global ischaemia (Steinberg et al. 1989a ,b, Himori et al. 1992 , Aronowski et al. 1993 , Graham et al. 1993 . Using a
